At the time of writing, ITeos Therapeutics Inc [ITOS] stock is trading at $6.51, up 4.66%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ITOS shares have gain 25.68% over the last week, with a monthly amount drifted -6.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ITeos Therapeutics Inc [NASDAQ: ITOS] stock has seen the most recent analyst activity on August 13, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $31. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 05, 2021, and set its price target to $37. On October 08, 2020, Robert W. Baird initiated with a Outperform rating and assigned a price target of $45 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $45 on August 18, 2020. SVB Leerink initiated its recommendation with a Outperform and recommended $45 as its price target on August 18, 2020. Piper Sandler started tracking with a Overweight rating for this stock on August 18, 2020, and assigned it a price target of $50. In a note dated August 18, 2020, JP Morgan initiated an Overweight rating and provided a target price of $40 on this stock.
For the past year, the stock price of ITeos Therapeutics Inc fluctuated between $4.80 and $18.75. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. ITeos Therapeutics Inc [NASDAQ: ITOS] shares were valued at $6.51 at the most recent close of the market. An investor can expect a potential return of 161.14% based on the average ITOS price forecast.
Analyzing the ITOS fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -4.56%, Pretax Profit Margin comes in at -3.49%, and Net Profit Margin reading is -3.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.22 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.13 points at the first support level, and at 5.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.72, and for the 2nd resistance point, it is at 6.94.
Ratios To Look Out For
It is important to note that ITeos Therapeutics Inc [NASDAQ:ITOS] has a current ratio of 12.62. Also, the Quick Ratio is 12.62, while the Cash Ratio stands at 3.52. Considering the valuation of this stock, the price to sales ratio is 7.10, the price to book ratio is 0.40.
Transactions by insiders
Recent insider trading involved Gall Matthew, Chief Financial Officer, that happened on Nov 19 ’24 when 5000.0 shares were purchased.
